BURLINGTON, N.C., Aug. 18, 2025 /PRNewswire/ -- Labcorp, a global leader of innovative and comprehensive laboratory services, announced today the availability of the Lumipulse® pTau-217/Beta Amyloid ...
Labcorp Holdings, Inc. LH has announced the nationwide availability of the Lumipulse pTau-217/Beta Amyloid 42 Ratio — the first FDA-cleared blood-based in-vitro diagnostic (IVD) test to assist in ...
Lumipulse® pTau-217/Beta Amyloid 42 Ratio now available nationwide through Labcorp BURLINGTON, N.C., Aug. 18, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive ...
BURLINGTON, N.C., Oct. 23, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer the Elecsys pTau181 test, the ...
Labcorp plans to offer Roche’s recently FDA-cleared blood test to assess early signs of Alzheimer’s disease and other causes of cognitive decline for patients 55 years and older. The blood test, which ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min As the number of Americans at ...
米ノースカロライナ州バーリントン - 世界有数のライフサイエンス企業であるLaboratory Corporation of America Holdings(以下、Labcorp、本社所在地:米国ノースカロライナ州バーリントン、ニューヨーク証券取引所上場 証券コード: LH)は本日、同社製薬開発事業部門 ...
戦略的パートナーシップを通じ、新施設の開発、国際共同治験のためのサービス強化へ 米ノースカロライナ州バーリントン - 世界有数のライフサイエンス企業であるLaboratory Corporation of America Holdings(以下、Labcorp、本社所在地:米国ノースカロライナ州 ...